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Background: In patients with chronic lymphocytic leukemia (CLL)
treated with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, intol-
erance was the most common reason for discontinuation (50% to
63%; Mato AR, et al. Haematologica. 2018). This Phase 2 trial evalu-
ated acalabrutinib, a highly selective, potent, covalent BTK inhibitor,
in ibrutinib-intolerant patients with relapsed/refractory CLL.
Methods: Patients with relapsed/refractory CLL (≥1 prior therapy)
who discontinued ibrutinib due to Grade 3/4 adverse events or
persistent/recurrent Grade 2 adverse events and had progressive dis-
ease after ibrutinib discontinuation were eligible. Acalabrutinib was
given orally at 100 mg twice daily in 28-day cycles until progressive
disease or unacceptable toxicity. The primary endpoint was overall
response rate.
Results: Sixty patients were treated. The median age was 70 years
(range, 43 to 88). Patient characteristics included bulky disease ≥5 cm
(33%), Rai stage III/IV (47%), del17p (28%), del11q (23%), and
unmutated IGHV (79%). Fifty-two of 55 patients (95%) with available
baseline samples were wild type forBTK and PLCG2. The median num-
ber of prior therapies was 2 (range, 1 to 10). The median duration of
prior ibrutinib therapy was 6 months (range, <1 to 55); common
adverse events that led to ibrutinib discontinuation were atrial
fibrillation/flutter (25%), diarrhea (12%), arthralgia (10%), and rash
(12%). At a median follow-up of 19 months (range, 1 to 31), 67% of
patients remain on acalabrutinib; discontinuations were mostly due to
progressive disease (13%) and adverse events (10%; pneumonia [n=2],
diarrhea, headache, ascites, arthralgia, subdural hematoma [all n=1]).
Efficacy outcomes are in the Table. Common adverse events (any
grade) were diarrhea (48%), headache (40%), contusion (35%), and diz-
ziness (32%). Serious adverse events (≥2 patients) were pneumonia
(10%), anemia (3%), and syncope (3%). Atrial fibrillation occurred in
3 patients (5%; all Grade 1/2) and major hemorrhage in 2 (3%; Grade
3 hematuria and Grade 2 subdural hematoma). Grade 5 adverse
events were pneumonia (n=2), bronchopulmonary aspergillosis (n=1),
and ventricular fibrillation (n=1); all were considered not related to
treatment.
Conclusions: Acalabrutinib is tolerable and effective in ibrutinib-
intolerant patients, providing a viable strategy for continuing BTK
inhibitor therapy.
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TABLE 1
N=60
Overall response rate (≥ PRL), n (%) 46 (77)
95% CI 64, 87
CR 1 (2)
PR 42 (70)
PRL 3 (5)
Median PFS Not reached
21-month PFS rate, % (95% CI) 76 (61, 86)
Abbreviations: CR, complete response; PFS, progression-free survival;
PR, partial response; PRL, partial response with lymphocytosis.
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Background: Despite recent advances, follicular lymphoma
(FL) remains incurable for most patients (pts). Relapsed/refractory (r/r)
FL is associated with decremental treatment responses, accumulating
toxicity, and poor survival among early failures of 1st line chemo-
immunotherapy. Underscored by the recent approvals of idelalisib,
copanlisib, and duvelisib, targeting B-cell receptor (BCR) signaling pro-
duces ORR of ~50% in r/r pts; however, new agents with a better
therapeutic index over long-term administration are needed.
SYK is a key regulator of BCR signaling (upstream of BTK and PI3K),
and its inhibition results in clinical activity in FL. Compared with unaf-
fected nodes, lymph nodes from FL pts have greater numbers of follic-
ular helper T cells that express high levels of IL-4, which may support
the tumor via the JAK1/3 pathway.
Cerdulatinib, an oral, reversible inhibitor of SYK and JAK kinases
(JAK1, JAK3, TYK2), previously reported a ~45% ORR in r/r FL as a
single agent. Xenograft studies suggest cerdulatinib may combine with
rituximab to enhance antitumor activity. We report updated results
from a Ph2a study of single-agent cerdulatinib and initial results in
combination with rituximab in r/r FL.
Methods: This Ph2a study confirmed the safety and efficacy of
cerdulatinib 30 mg BID in r/r B- and T-cell lymphoma pts. Dose reduc-
tions were permitted to 15 mg BID. Response was assessed by
Lugano criteria.
Results: As of Jan 2019, enrollment was 40 pts in the single-agent
cohort and 11 in the rituximab combination cohort. Median (range) age
was 64 (42-81) and median prior therapies was 3 (1-8). Fifty (98%) pts
had prior anti-CD20 therapy, and 8 (16%) had prior PI3K or BTK inhibi-
tors. The most common AEs of any grade were diarrhea (47%), nausea
(37%), lipase increase (29%), and amylase increase (22%). Grade 3+ AEs
in ≥5% pts were lipase increase (24%), diarrhea (12%), amylase increase
(10%), nausea (8%), hypertension (8%), and neutropenia (6%). Grade 3+
infections occurred in 6 (12%) pts. One pt had grade 5 multi-organ fail-
ure potentially related to study drug. Amylase and lipase increases gen-
erally were not associated with abdominal pain or pancreatitis. The
safety profile appeared similar in both cohorts.
The ORR was 46% as a single agent (5 CRs, 13 PRs in 40 pts) and 67%
in the combination cohort (4/6 PRs; 2 pts with SD had a >40%
reduction in tumor volume at 1st re-scan). Responses typically
occurred after 2 cycles and were durable in the single-agent cohort,
with 10 pts on drug for >1 year. Enrollment in the combination cohort
is ongoing. Updated safety and efficacy will be presented.
Conclusion: The recommended cerdulatinib Ph2 dose of 30 mg BID
was tolerable and efficacious in heavily pretreated r/r FL. The
cerdulatinib + rituximab combination appears to be well tolerated,
with tumor reductions in all evaluable pts. The safety profile and
unique MOA of cerdulatinib support further combination stud-
ies in FL.
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